Mid-term Outcomes of the Ross II Procedure in Infants and Young Children with Irreparable Mitral Disease

Le résumé fourni par la source

OBJECTIVES: We aimed to summarize the clinical implications and outcomes of the Ross II procedure for infants and young children. METHODS: This study retrospectively reviewed consecutive paediatric patients who underwent Ross II procedure from 2011 to 2022 at Fuwai Hospital. Baseline, operative, postoperative characteristics, and outcomes were summarized. Postoperative all-cause mortality was defined as the primary outcome, and reoperation as the secondary outcome. RESULTS: Ten patients who underwent the Ross II procedure were included in the final analysis, with 2 cases of late mortality and 3 cases of reoperation during a median follow-up of 36 months (range: 3.5 months to 9 years). The median age at surgery was 1.8 years (interquartile range [IQR]: 0.65 to 3.5), and the median mitral annulus diameter was 16 mm (IQR: 15 to 18). Patients who underwent the Ross II procedure experienced a prolonged postoperative course, with a median intensive care unit stay of 11.5 days (IQR: 8.5 to 19.75) and postoperative hospital stay of 24 days (IQR: 20.25 to 34.75). Mitral stenosis emerged as the predominant late complication following the Ross II procedure, affecting 80% patients, as evidenced by the increase in mean gradient 3 years postoperatively compared with discharge. CONCLUSIONS: The Ross II procedure may represent a safe option for infants and young children when prosthetic valves are unavailable, despite the limited growth potential of the pulmonary autograft.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.